Redeye provides its comment on Mendus’ Q1 2024 report. Encouragingly, the company has recently received the ethics committee greenlight for CADENCE, and we understand the trial initiated patient recruitment in
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source